维生素D受体激活剂安全性概况的比较分析:基于EudraVigilance数据库的药监测研究
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
维生素D受体 (VDR) 激动剂具有不同的安全性. 活跃的VDR激动剂需要对严重并发症进行监测,而胆胆醇的风险较小,特别是在儿童中.
科学领域:
- 药物监督 药物监督 药物监督
- 内分泌学 在内分泌学.
- 药品安全 药品安全
背景情况:
- 维生素D受体 (VDR) 激动剂广泛用于调节.
- 对于VDR激动剂,特别是食补充剂,现实世界的安全数据有限.
- 了解VDR激动剂的安全性对于临床实践至关重要.
研究的目的:
- 分析VDR激动剂的安全性概况.
- 为了确定与VDR激动剂相关的不良药物反应 (ADRs).
- 为了比较不同VDR激动剂化合物的安全性.
主要方法:
- 利用EudraVigilance数据库对2004年至2024年的ADR报告进行分析.
- 分析了十种VDR激动剂的数据,重点关注特定的安全信号.
- 使用后勤回归来评估副作用的风险因素.
主要成果:
- 17,947份报告 (0.33%) 的80,050个ADR与VDR激动剂有关.
- 胆醇和酸是报告最多的VDR激动剂.
- 高血症是关键的ADR,二太基醇,阿尔法醇和酸的风险最高.
- 活跃的VDR激动剂与严重并发症有关;胆醇与胃肠道症状有关,特别是在儿童中.
结论:
- 根据化合物,VDR激动剂的安全概况因化合物而异.
- 活跃的VDR激动剂需要密切监测与血热有关的问题.
- 胆甲醇表现出更安全的特征,较少严重的副作用,特别是在儿科患者群体中.
更多相关视频
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Regulation
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Hazard Ratio
For example, in a clinical trial...
Clinical Trials: Overview
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
